{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:06:11Z","timestamp":1768277171815,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.tripleo.2006.12.004","type":"journal-article","created":{"date-parts":[[2007,4,21]],"date-time":"2007-04-21T11:10:29Z","timestamp":1177153829000},"page":"186-193","source":"Crossref","is-referenced-by-count":63,"title":["Bisphosphonates and osteonecrosis of the jaws: Science and rationale"],"prefix":"10.1016","volume":"104","author":[{"given":"Rajesh","family":"Gutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Louis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tripleo.2006.12.004_bib1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1053\/joms.2000.8744","article-title":"Neuropathic pain in maxillofacial osteonecrosis","volume":"58","author":"Bouquot","year":"2000","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2006.12.004_bib2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/sarh.2002.33724b","article-title":"Pathogenesis and natural history of osteonecrosis","volume":"32","author":"Assouline-Dayan","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2006.12.004_bib3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0022-2143(96)90065-7","article-title":"The pathophysiology of alveolar osteonecrosis of the jaw: anticardiolipin antibodies, thrombophilia, and hypofibrinolysis","volume":"127","author":"Gruppo","year":"1996","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.tripleo.2006.12.004_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jlac.18651330307","article-title":"Ueber die Einwirkung des Chloracetyls auf phosphorige S\u00e4ure","volume":"133","author":"Menschutkin","year":"1865","journal-title":"Ann Chem Pharm"},{"key":"10.1016\/j.tripleo.2006.12.004_bib5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.165.3899.1264","article-title":"Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo","volume":"165","author":"Francis","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.tripleo.2006.12.004_bib6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/212901a0","article-title":"Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis","volume":"212","author":"Fleisch","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.tripleo.2006.12.004_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2362.1970.tb00591.x","article-title":"The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo","volume":"1","author":"Fleisch","year":"1970","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.tripleo.2006.12.004_bib8","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","article-title":"Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo","volume":"165","author":"Fleisch","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.tripleo.2006.12.004_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF02555748","article-title":"Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat","volume":"38","author":"Schenk","year":"1986","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 4","key":"10.1016\/j.tripleo.2006.12.004_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","author":"Conte","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.tripleo.2006.12.004_bib11","first-page":"265","article-title":"Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives","volume":"54","author":"Bisaz","year":"1978","journal-title":"Clin Sci Mol Med"},{"key":"10.1016\/j.tripleo.2006.12.004_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jbmr.5650070507","article-title":"Retention of etidronate in human, dog, and rat","volume":"7","author":"Kasting","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02408534","article-title":"Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD) in rats","volume":"32","author":"Reitsma","year":"1980","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.tripleo.2006.12.004_bib14","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/mol.61.5.1255","article-title":"Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP\/ATP translocase by a nonhydrolyzable, adenine-containing metabolite","volume":"61","author":"Lehenkari","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11914-003-0008-5","article-title":"Mechanism of action of bisphosphonates","volume":"1","author":"Reszka","year":"2003","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.tripleo.2006.12.004_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S8756-3282(95)00150-6","article-title":"A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders","volume":"17","author":"Murakami","year":"1995","journal-title":"Bone"},{"issue":"Suppl 2","key":"10.1016\/j.tripleo.2006.12.004_bib17","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0960-9776(03)80162-5","article-title":"Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions","volume":"12","author":"Body","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.tripleo.2006.12.004_bib18","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.tripleo.2006.12.004_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1126\/science.279.5350.509","article-title":"Rho GTPases and the actin cytoskeleton","volume":"279","author":"Hall","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.tripleo.2006.12.004_bib21","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tripleo.2006.12.004_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF03032599","article-title":"The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis","volume":"7","author":"John","year":"2001","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib23","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","article-title":"Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?","volume":"63","author":"Hellstein","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2006.12.004_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/8756-3282(95)00426-2","article-title":"Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures","volume":"18","author":"Niskikawa","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.tripleo.2006.12.004_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jbmr.5650020209","article-title":"Effect of bisphosphonates on proliferation and viability of mouse bone marrow\u2013derived macrophages","volume":"2","author":"Cecchini","year":"1987","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib26","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/jbmr.5650111017","article-title":"The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+ ATPase","volume":"11","author":"David","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0005-2744(76)90291-6","article-title":"The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes","volume":"429","author":"Felix","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tripleo.2006.12.004_bib28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1359\/jbmr.1997.12.6.869","article-title":"Regulation of osteoclast function","volume":"12","author":"Suda","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.tripleo.2006.12.004_bib30","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6600986","article-title":"Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.tripleo.2006.12.004_bib31","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.bjc.6600297","article-title":"The bisphosphonate zoledronic acid impairs Ras membrane localisation and induces cytochrome c release in breast cancer cells","volume":"86","author":"Senaratne","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.tripleo.2006.12.004_bib32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1359\/jbmr.1999.14.5.784","article-title":"The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium","volume":"14","author":"Twiss","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0093-7754(01)90263-5","article-title":"Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment","volume":"28","author":"Mundy","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib34","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(69)92293-4","article-title":"Diphosphonates in the treatment of myositis ossificans","volume":"2","author":"Bassett","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.tripleo.2006.12.004_bib35","series-title":"Bisphosphonates on bone","author":"Bijvoet","year":"1995"},{"key":"10.1016\/j.tripleo.2006.12.004_bib36","first-page":"61","article-title":"The control of dental calculus in experimental animals","volume":"21","author":"Briner","year":"1971","journal-title":"Int Dent J"},{"key":"10.1016\/j.tripleo.2006.12.004_bib37","first-page":"31","article-title":"Effect of diphosphonate on human supragingival calculus","volume":"14","author":"M\u00fchlemann","year":"1970","journal-title":"Helv Odont Acta"},{"key":"10.1016\/j.tripleo.2006.12.004_bib38","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1902\/jop.1971.42.7.416","article-title":"Reduction of dental calculus in humans through the use of a dentifrice containing a crystal-growth inhibitor","volume":"42","author":"Sturzenberger","year":"1971","journal-title":"J Periodontol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib39","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199702203360807","article-title":"The management of Paget\u2019s disease of bone","volume":"336","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tripleo.2006.12.004_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib41","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199808063390609","article-title":"Bisphosphonates as anticancer drugs","volume":"339","author":"Mundy","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tripleo.2006.12.004_bib42","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0140-6736(89)91791-1","article-title":"Comparison of 3 bisphosphonates in cancer-associated hypercalcaemia","volume":"2","author":"Ralston","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.tripleo.2006.12.004_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1742-1241.1996.tb09530.x","article-title":"Alendronate: a new bisphosphonate for the treatment of osteoporosis","volume":"50","author":"Keen","year":"1996","journal-title":"Br J Clin Pract"},{"key":"10.1016\/j.tripleo.2006.12.004_bib44","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(89)92927-9","article-title":"Prevention of postmenopausal bone loss by tiludronate","volume":"2","author":"Reginster","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.tripleo.2006.12.004_bib45","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/01.RES.42.4.562","article-title":"The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits","volume":"42","author":"Kramsch","year":"1978","journal-title":"Circ Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1677\/erc.1.01094","article-title":"A Emerging anticancer molecular mechanisms of aminobisphosphonates","volume":"13","author":"Caraglia","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.tripleo.2006.12.004_bib47","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib48","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.joms.2003.09.001","article-title":"Avascular necrosis of the jaws: risk factors in metastatic cancer patients","volume":"61","author":"Tarassoff","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2006.12.004_bib49","first-page":"74","article-title":"Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report","volume":"10","author":"Starck","year":"1995","journal-title":"Int J Oral Maxillofac Implants"},{"key":"10.1016\/j.tripleo.2006.12.004_bib50","series-title":"Updated safety: possible relationship of Aredia (pamidronate disodium) and\/or Zometa (zoledronic acid) with osteonecrosis of the jaw","year":"2004"},{"key":"10.1016\/j.tripleo.2006.12.004_bib51","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib52","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib53","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF02008217","article-title":"The short-term effects of high doses of ethylene-1-hydroxy-1,1-diphosphonates upon early dentin formation","volume":"16","author":"Larsson","year":"1974","journal-title":"Calcif Tissue Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib55","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0003-9969(90)90064-H","article-title":"Effects of single doses of 1-hydroxyethylidene-1,1-bisphosphonate (HEBP) on the mineralizing front of rat incisor enamel: a microradiographic and scanning electron microscopic study","volume":"35","author":"Weile","year":"1990","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib56","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/00016359609003511","article-title":"Root surface defects in rat molar induced by 1-hydroxyethylidene-1,1-bisphosphonate","volume":"54","author":"Alatli","year":"1996","journal-title":"Acta Odontol Scand"},{"key":"10.1016\/j.tripleo.2006.12.004_bib57","first-page":"389","article-title":"Comparative skeletal effects of two diphosphonates in dogs","volume":"2","author":"Flora","year":"1980","journal-title":"Metab Bone Dis Rel Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib58","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib59","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","article-title":"Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years","volume":"10","author":"Guarneri","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.tripleo.2006.12.004_bib60","series-title":"Industrial maladies","author":"Legge","year":"1934"},{"key":"10.1016\/j.tripleo.2006.12.004_bib61","first-page":"343","article-title":"Phosphorus necrosis under control","volume":"76","year":"1944","journal-title":"Br Dent J"},{"key":"10.1016\/j.tripleo.2006.12.004_bib62","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/0002-9343(85)90057-9","article-title":"Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosis","volume":"79","author":"Zigic","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.tripleo.2006.12.004_bib63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jbmr.5650080211","article-title":"Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis","volume":"8","author":"Storm","year":"1993","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tripleo.2006.12.004_bib64","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1172\/JCI116872","article-title":"The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates","volume":"92","author":"Balena","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tripleo.2006.12.004_bib65","unstructured":"Damato K, Gralow J, Hoff A, Huryn J, Marx RE, Ruggiero S, et al. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/briefing\/2005-4095B2_02_12-Novartis-Zometa-App-11.pdf. (Accessed May 4, 2005)."},{"key":"10.1016\/j.tripleo.2006.12.004_bib66","unstructured":"AAOMS Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. Available at: http:\/\/aaoms.org\/docs\/position_papers\/osteonecrosis.pdf. (Accessed October 5, 2006)."},{"key":"10.1016\/j.tripleo.2006.12.004_bib67","doi-asserted-by":"crossref","first-page":"48213","DOI":"10.1074\/jbc.M106473200","article-title":"Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages","volume":"276","author":"Coxon","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tripleo.2006.12.004_bib68","first-page":"1","article-title":"Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours","volume":"12","author":"Caraglia","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.tripleo.2006.12.004_bib69","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tripleo.2006.12.004_bib70","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210406009681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210406009681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T15:03:44Z","timestamp":1707836624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079210406009681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S1079210406009681"],"URL":"https:\/\/doi.org\/10.1016\/j.tripleo.2006.12.004","relation":{},"ISSN":["1079-2104"],"issn-type":[{"value":"1079-2104","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}